UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Journal of medicinal chemistry, 2007-11, Vol.50 (22), p.5339-5356

2007

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Journal of medicinal chemistry, 2005-03, Vol.48 (6), p.1729-1744

2005

Link zum Volltext

Verfügbarkeit prüfen

Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries : A quantitative coronary angiography and three-dimensional intravascular ultrasound study

Circulation (New York, N.Y.), 2001-01, Vol.103 (2), p.192-195

2001

Link zum Volltext

Verfügbarkeit prüfen

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

European journal of drug metabolism and pharmacokinetics, 2011-09, Vol.36 (3), p.129-139

2011

Link zum Volltext

Verfügbarkeit prüfen

Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure

Journal of the American College of Cardiology, 2006-09, Vol.48 (6), p.1217-1224

2006

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for the management of patients with obstructive sleep apnoea and hypertension

The European respiratory journal, 2013-03, Vol.41 (3), p.523-538

2013

Link zum Volltext

Verfügbarkeit prüfen

Structure-Based Design of Novel Guanidine/Benzamidine Mimics: Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants

Journal of medicinal chemistry, 2003-10, Vol.46 (21), p.4405-4418

2003

Link zum Volltext

Verfügbarkeit prüfen

Rare Deletions at the Neurexin 3 Locus in Autism Spectrum Disorder

American journal of human genetics, 2012-01, Vol.90 (1), p.133-141

2012

Link zum Volltext

Verfügbarkeit prüfen

Structure–activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors

Bioorganic & medicinal chemistry, 2008-01, Vol.18 (2), p.749-754

2008

Link zum Volltext

Verfügbarkeit prüfen

Sirolimus-eluting stent for the treatment of in-stent restenosis: A quantitative coronary angiography and three-dimensional intravascular ultrasound study

Circulation (New York, N.Y.), 2003-01, Vol.107 (1), p.24-27

2003

Link zum Volltext

Verfügbarkeit prüfen

Structure–activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties

Bioorganic & medicinal chemistry letters, 2008-05, Vol.18 (9), p.2845-2849

2008

Link zum Volltext

Verfügbarkeit prüfen

Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties

Bioorganic & medicinal chemistry letters, 2006-11, Vol.16 (21), p.5584-5589

2006

Link zum Volltext

Verfügbarkeit prüfen

N-in-1 Dosing Pharmacokinetics in Drug Discovery: Experience, Theoretical and Practical Considerations

Journal of pharmaceutical sciences, 2008-07, Vol.97 (7), p.2568-2580

2008

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Journal of medicinal chemistry, 2003-12, Vol.46 (25), p.5298-5315

2003

Link zum Volltext

Verfügbarkeit prüfen

Effect of Lung Volume Reduction Surgery on Diaphragmatic Neuromechanical Coupling At 2 Years

Chest, 2004-06, Vol.125 (6), p.2188-2195

2004

Link zum Volltext

Verfügbarkeit prüfen

Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues

Bioorganic & medicinal chemistry letters, 2007-03, Vol.17 (5), p.1432-1437

2007

Link zum Volltext

Verfügbarkeit prüfen

Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm

American journal of respiratory and critical care medicine, 1998-02, Vol.157 (2), p.475-483

1998

Link zum Volltext

Verfügbarkeit prüfen

Metabolism of the cysteine S-conjugate of busulfan involves a beta-lyase reaction

Drug metabolism and disposition, 2008-08, Vol.36 (8), p.1546

2008

Link zum Volltext

Verfügbarkeit prüfen

Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo

Circulation (New York, N.Y.), 1999-05, Vol.99 (19), p.2590-2597

1999

Link zum Volltext

Verfügbarkeit prüfen

Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)

Journal of inherited metabolic disease, 2009-08, Vol.32 (4), p.534-543

2009

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones

Bioorganic & medicinal chemistry letters, 1999-02, Vol.9 (3), p.443-448

1999

Link zum Volltext

Verfügbarkeit prüfen

Identification of germ-line E-cadherin mutations in gastric cancer families of European origin

Cancer research (Chicago, Ill.), 1998-09, Vol.58 (18), p.4086-4089

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Medical Sciences
(35)
Science & Technology
(35)
Pharmacology. Drug Treatments
(24)
Humans
(20)
Pharmacology & Pharmacy
(20)
Animals
(19)
Chemistry, Medicinal
(18)
Male
(14)
Female
(13)
Chemistry
(12)
Physical Sciences
(12)
Blood. Blood Coagulation. Reticuloendothelial System
(11)
Chemistry, Organic
(11)
Dogs
(9)
Factor Xa Inhibitors
(9)
Structure-Activity Relationship
(9)
Models, Molecular
(8)
Middle Aged
(7)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries : A quantitative coronary angiography and three-dimensional intravascular ultrasound study

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure

Recommendations for the management of patients with obstructive sleep apnoea and hypertension

Structure-Based Design of Novel Guanidine/Benzamidine Mimics: Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants

Rare Deletions at the Neurexin 3 Locus in Autism Spectrum Disorder

Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Structure–activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors

Sirolimus-eluting stent for the treatment of in-stent restenosis: A quantitative coronary angiography and three-dimensional intravascular ultrasound study

Structure–activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties

Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties

International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009

N-in-1 Dosing Pharmacokinetics in Drug Discovery: Experience, Theoretical and Practical Considerations

Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-( R)-hydroxy- N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4- c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa

Effect of Lung Volume Reduction Surgery on Diaphragmatic Neuromechanical Coupling At 2 Years

Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues

Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm

Metabolism of the cysteine S-conjugate of busulfan involves a beta-lyase reaction

Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo

Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)

Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones

Identification of germ-line E-cadherin mutations in gastric cancer families of European origin

Aktive Filter

Suchergebnisse filtern